DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Italy Fines Apple €98.6 Million Over App Store Dominance 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
MENLO PARK, Calif., Oct. 26, 2016 -- Geron Corporation (Nasdaq:GERN) will announce its financial results for the third quarter ended September 30, 2016, on Thursday, November 3, 2016, after the market close. Geron’s management will also host a conference call for analysts and investors on Thursday, November 3, 2016, at 4:30 p.m. Eastern Time to discuss the company’s third quarter results and recent events.
Participants can access the conference call live via telephone by dialing 877-303-9139 (U.S.); 760-536-5195 (international). The conference ID is 6488635. If accessing the conference call by telephone, please dial in at least 10 minutes early to minimize any delay in joining the call. A live audio-only webcast is also available at http://edge.media-server.com/m/p/ci36i65z. The audio webcast of the conference call will be available for replay approximately one hour following the live broadcast through December 4, 2016.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
